Quoin Pharmaceuticals Ltd. American Depositary Shares (QNRX)
Stock · NASDAQ · Health Care
$4.03as of 10/16/2026
Price chart
Active signals
QNRX Signal Track Record
How signals performed across all stocks →What QNRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 21 | -21.6% | 10% | September 2, 2026 |
| Volume Spike | 20 | -18.8% | 30% | October 6, 2026 |
| Bollinger Band Breakdown | 16 | -15.4% | 31% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -21.1% | 33% | November 7, 2025 |
| Any 20-session window (baseline) | -8.1% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QNRX
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- quoinpharma.com/
Fundamentals
- 1-day range
- $3.9$4.11
- Market cap
- $9.18M
- P/E (trailing)
- —
- P/E (forward)
- -1.22
- EPS (trailing)
- $-12.11
- Dividend yield
- —
- Beta
- 1.69
- Avg. volume
- 544.2K
- Dividend pay date
- October 23, 2019
Forecasts
7 analyst ratings
Quoin Pharmaceuticals Ltd. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- QNRXQuoin Pharmaceuticals Ltd. American Depositary Shares$3.9▼ 3.23%Market cap $9.18MP/E —$3.25$23.5
- ASBPAspire Biopharma Holdings Inc. Common Stock$8.78▲ 1.62%Market cap $9.14MP/E —$3.31$562.8
- IMRNImmuron Limited American Depositary Shares$0.982▼ 4.66%Market cap $8.88MP/E —$0.026$0.098
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
- LEXXLexaria Bioscience Corp. Common Stock$2.86▼ 4.35%Market cap $8.82MP/E —$2.43$21.6
- LSTALisata Therapeutics Inc. Common Stock$1.03▼ 3.74%Market cap $9.74MP/E —$0.98$5.07
- XCURExicure Inc. Common Stock$1.12▲ 0.00%Market cap $8.60MP/E —$0.936$9.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals Ltd. American Depositary Shares | $9.18M | — | $3.9 | ▼ 3.23% | $3.25$23.5 |
| ASBP Aspire Biopharma Holdings Inc. Common Stock | $9.14M | — | $8.78 | ▲ 1.62% | $3.31$562.8 |
| IMRN Immuron Limited American Depositary Shares | $8.88M | — | $0.982 | ▼ 4.66% | $0.026$0.098 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
| LEXX Lexaria Bioscience Corp. Common Stock | $8.82M | — | $2.86 | ▼ 4.35% | $2.43$21.6 |
| LSTA Lisata Therapeutics Inc. Common Stock | $9.74M | — | $1.03 | ▼ 3.74% | $0.98$5.07 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.12 | ▲ 0.00% | $0.936$9.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndromebenzinga · 10/14/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 10/7/2026
- Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and TherapyYahoo · 10/6/2026
- Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy IssueBenzinga · 10/6/2026
- Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20Benzinga · 9/23/2026
- Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeYahoo · 9/22/2026
Insider Activity
Insider Actions →- Denise P. Carter · August 31, 2026 · Buy10.2K
- Denise P. Carter · August 31, 2026 · Buy20.5K @ $4.88
- Michael Myers · August 31, 2026 · Buy10.2K
- Michael Myers · August 31, 2026 · Buy20.5K @ $4.88
- Lawlor Sally Bridget · August 31, 2026 · Buy5.1K
- Lawlor Sally Bridget · August 31, 2026 · Buy10.2K @ $4.88
- Anthony James Culverwell · August 31, 2026 · Buy3.1K
- Anthony James Culverwell · August 31, 2026 · Buy6.1K @ $4.88
- Dennis Langer · August 27, 2026 · Grant34.5K @ $5.15
- Anthony James Culverwell · August 27, 2026 · Grant31.4K @ $5.15
Institutional Ownership
March 31, 2026
- Total shares held
- 1.18M
- Total value held
- $7.82M
- Institutional holders
- 21
- Unknown211.5K
- Unknown196.6K
- Unknown100.3K
- Unknown84.8K
- Unknown79.6K
- Unknown76.2K
- Unknown75.0K
- Unknown72.7K
- Unknown60.0K
- Unknown59.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
QNRX: Manuscript Acceptance for QRX003 in Dermatology
Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.
QNRX: Manuscript Acceptance for QRX003 in Dermatology. Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.